JP2004533457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533457A5 JP2004533457A5 JP2003500062A JP2003500062A JP2004533457A5 JP 2004533457 A5 JP2004533457 A5 JP 2004533457A5 JP 2003500062 A JP2003500062 A JP 2003500062A JP 2003500062 A JP2003500062 A JP 2003500062A JP 2004533457 A5 JP2004533457 A5 JP 2004533457A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- sulfonamide
- ylmethylphenyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 62
- 239000002671 adjuvant Substances 0.000 claims 10
- 239000003085 diluting agent Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- -1 n- butyl Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 201000006549 dyspepsia Diseases 0.000 claims 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 101150116411 AGTR2 gene Proteins 0.000 claims 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- IYZVAOAMGHOEHC-UHFFFAOYSA-N C(=O)=NS(=O)(=O)C=1SC(=CC=1C1=CC=C(C=C1)CN1C=NC=C1)CC(C)C Chemical compound C(=O)=NS(=O)(=O)C=1SC(=CC=1C1=CC=C(C=C1)CN1C=NC=C1)CC(C)C IYZVAOAMGHOEHC-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 206010013781 dry mouth Diseases 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 230000001969 hypertrophic effect Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- QMKDXFGVHANNCT-UHFFFAOYSA-N 1-butyl-3-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylurea Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)NCCCC QMKDXFGVHANNCT-UHFFFAOYSA-N 0.000 claims 1
- LVOSHIKIHCLWMB-UHFFFAOYSA-N 2-butoxy-n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylacetamide Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)COCCCC LVOSHIKIHCLWMB-UHFFFAOYSA-N 0.000 claims 1
- UZDLZKANCYDPSR-UHFFFAOYSA-N 2-methylpropyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCC(C)C UZDLZKANCYDPSR-UHFFFAOYSA-N 0.000 claims 1
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000002881 Colic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010020601 Hyperchlorhydria Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000011707 Ovulation disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000005946 Xerostomia Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000008484 agonism Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- IEKPELSFCDOQBA-UHFFFAOYSA-N butyl n-[2-[4-(imidazol-1-ylmethyl)phenyl]-4-(2-methylpropyl)phenyl]sulfonylcarbamate Chemical compound CCCCOC(=O)NS(=O)(=O)C1=CC=C(CC(C)C)C=C1C(C=C1)=CC=C1CN1C=NC=C1 IEKPELSFCDOQBA-UHFFFAOYSA-N 0.000 claims 1
- LBMNAFHGVMWZLF-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methoxyethyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CCOC)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC LBMNAFHGVMWZLF-UHFFFAOYSA-N 0.000 claims 1
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 claims 1
- FTQCYFZKKZBBDO-UHFFFAOYSA-N butyl n-[3-[4-[(4-methylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=C(C)N=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC FTQCYFZKKZBBDO-UHFFFAOYSA-N 0.000 claims 1
- CRVUTXCUTSEMJG-UHFFFAOYSA-N butyl n-[5-(2-methylpropyl)-3-[4-(1,2,4-triazol-1-ylmethyl)phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3N=CN=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC CRVUTXCUTSEMJG-UHFFFAOYSA-N 0.000 claims 1
- ALBUOUSMHVDYPH-UHFFFAOYSA-N butyl n-[5-(2-methylpropyl)-3-[4-(pyrazol-1-ylmethyl)phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3N=CC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC ALBUOUSMHVDYPH-UHFFFAOYSA-N 0.000 claims 1
- YEYBCQMOQPDMCY-UHFFFAOYSA-N butyl n-[5-(2-methylpropyl)-3-[4-(tetrazol-1-ylmethyl)phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3N=NN=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC YEYBCQMOQPDMCY-UHFFFAOYSA-N 0.000 claims 1
- BOAVWPQXLAYBQX-UHFFFAOYSA-N butyl n-[5-(2-methylpropyl)-3-[4-(tetrazol-2-ylmethyl)phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3N=NC=N3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC BOAVWPQXLAYBQX-UHFFFAOYSA-N 0.000 claims 1
- WIECBDQRUBNGNS-UHFFFAOYSA-N butyl n-[5-(2-methylpropyl)-3-[4-[[3-(trifluoromethyl)pyrazol-1-yl]methyl]phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3N=C(C=C3)C(F)(F)F)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC WIECBDQRUBNGNS-UHFFFAOYSA-N 0.000 claims 1
- LTJMWCDMMKPNCW-UHFFFAOYSA-N butyl n-[5-butyl-3-[4-(imidazol-1-ylmethyl)phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CCCC)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC LTJMWCDMMKPNCW-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- LPYXRTXXLKVWKJ-UHFFFAOYSA-N ethyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCC LPYXRTXXLKVWKJ-UHFFFAOYSA-N 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- JRELQXXPAXDOSZ-UHFFFAOYSA-N n-butylsulfonyl-3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-carboxamide Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1C(=O)NS(=O)(=O)CCCC JRELQXXPAXDOSZ-UHFFFAOYSA-N 0.000 claims 1
- NCVDBSQABWZGGA-UHFFFAOYSA-N n-butylsulfonyl-3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-sulfonamide Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NS(=O)(=O)CCCC NCVDBSQABWZGGA-UHFFFAOYSA-N 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000003961 neuronal insult Effects 0.000 claims 1
- 230000009689 neuronal regeneration Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000016087 ovulation Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- LIBZHQJJLOPSQZ-UHFFFAOYSA-N propan-2-yl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OC(C)C LIBZHQJJLOPSQZ-UHFFFAOYSA-N 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 206010038464 renal hypertension Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 206010044008 tonsillitis Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0113129.1 | 2001-05-31 | ||
| GB0113129A GB0113129D0 (en) | 2001-05-31 | 2001-05-31 | Pharmaceutically-useful compounds |
| GB0121611A GB0121611D0 (en) | 2001-09-07 | 2001-09-07 | Pharmaceutically-useful-compounds |
| GB0121611.8 | 2001-09-07 | ||
| US35095902P | 2002-01-25 | 2002-01-25 | |
| US60/350,959 | 2002-01-25 | ||
| GB0201794A GB0201794D0 (en) | 2002-01-26 | 2002-01-26 | Pharmaceutically-useful compounds |
| GB0201794.5 | 2002-01-26 | ||
| PCT/GB2002/002563 WO2002096883A1 (en) | 2001-05-31 | 2002-05-30 | Tricyclic compounds useful as angiotensin ii agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004533457A JP2004533457A (ja) | 2004-11-04 |
| JP2004533457A5 true JP2004533457A5 (https=) | 2006-01-05 |
| JP4707321B2 JP4707321B2 (ja) | 2011-06-22 |
Family
ID=32872450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003500062A Expired - Lifetime JP4707321B2 (ja) | 2001-05-31 | 2002-05-30 | アンギオテンシンｉｉアゴニストとして有用な三環式化合物 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4707321B2 (https=) |
| KR (1) | KR100938817B1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006235698B2 (en) * | 2005-04-12 | 2012-03-29 | Vicore Pharma Ab | New tricyclic angiotensin II agonists |
| US8461209B2 (en) * | 2007-06-20 | 2013-06-11 | Mitsubishi Tanabe Pharma Corporation | Malonic acid sulfonamide derivative and pharmaceutical use thereof |
| KR102230461B1 (ko) * | 2013-03-15 | 2021-03-22 | 유니버시티 오브 써던 캘리포니아 | 엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들 |
| US10071099B2 (en) | 2014-04-03 | 2018-09-11 | National Cerebral And Cardiovascular Center | Medicament for suppressing malignant tumor metastasis |
| GB201913603D0 (en) | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| KR20230004501A (ko) * | 2020-03-19 | 2023-01-06 | 바이코어 파마 아베 | 안지오텐신 ⅱ와 관련된 질병, 장애, 또는 병태의 치료 및/또는 예방에 유용한 신규 화합물 |
| GB202007122D0 (en) * | 2020-05-14 | 2020-07-01 | Vicore Pharma Ab | New process |
| GB202013721D0 (en) * | 2020-09-01 | 2020-10-14 | Vicore Pharma Ab | New compounds |
| EP4313953A1 (en) * | 2021-03-23 | 2024-02-07 | Vicore Pharma AB | Selective angiotensin ii receptor ligands |
| GB202104033D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| GB202104038D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| MX2024000518A (es) * | 2021-07-09 | 2024-01-31 | Vicore Pharma Ab | Nuevos compuestos selectivos de angiotensina ii. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5444067A (en) * | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
-
2002
- 2002-05-30 KR KR1020037015757A patent/KR100938817B1/ko not_active Expired - Fee Related
- 2002-05-30 JP JP2003500062A patent/JP4707321B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535899A5 (https=) | ||
| CN101925572B (zh) | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 | |
| CN103351389B (zh) | 卤代芳基取代的氨基嘌呤、其组合物，和将其用于治疗的方法 | |
| JP4598771B2 (ja) | 複素環式化合物 | |
| AU2007284562B2 (en) | Using PI3K and MEK modulators in treatments of cancer | |
| US5516775A (en) | Further use of pyrimidine derivatives | |
| JP2004533457A5 (https=) | ||
| EP1611123B1 (en) | Tie-2 modulators and methods of use | |
| AU2008214372A1 (en) | Therapeutic agents | |
| CA2449150A1 (en) | Tricyclic compounds useful as angiotensin ii agonists | |
| TW200412949A (en) | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | |
| BRPI0617162B1 (pt) | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos | |
| CN101622248A (zh) | 用作axl抑制剂的n3-杂芳基取代的三唑和n5-杂芳基取代的三唑 | |
| JP2016519165A (ja) | Ｗｎｔ経路モジュレーターとしてのプリンジオン | |
| MXPA05002644A (es) | Derivados de pirimidinona como agentes terapeuticos contra procesos de remodelacion, isquemicos e inflamatorios agudos y cronicos. | |
| TW202110833A (zh) | 新穎環狀緩激肽b2受體拮抗劑 | |
| JP2008535898A5 (https=) | ||
| JP2013514991A (ja) | Ｄｐｐ−１の阻害剤として有用な二環式誘導体 | |
| JP4007743B2 (ja) | 血管新生阻害剤 | |
| CN112390782B (zh) | 一种特异性增强TRPV4-KCa2.3复合体的空间耦联度的化合物及其用途 | |
| EA007595B1 (ru) | Производные имидазохинолина в качестве лигандов аденозиновых арецепторов | |
| RU2407742C2 (ru) | Производное бензимидазола и применение в качестве антагониста ангиотензина ii | |
| JP2009538851A (ja) | テトラヒドロピロロピリジン、テトラヒドロピラゾロピリジン、テトラヒドロイミダゾピリジンおよびテトラヒドロトリアゾロピリジン誘導体およびそれらの使用 | |
| JPH04261181A (ja) | 新規なヘトラゼピノイドアミド | |
| US6727266B2 (en) | Substituted tryptophan derivatives |